Transforming growth factor-β is a pleiotropic growth factor that has enthralled many investigators for approximately two decades. In addition to many reports that have clarified the basic mechanism of transforming growth factor-β signal transduction, numerous laboratories have published on the clinical implication/application of transforming growth factor-β. To name a few, dysregulation of transforming growth factor-β signaling plays a role in carcinogenesis, autoimmunity, angiogenesis, and wound healing. In this report, we will review these clinical implications of transforming growth factor-β.
Introduction
TGF-β signaling pathway's elucidation has shown it to be very complex with multiple levels of regulation, involved in many processes, including development, wound healing, fibrosis, carcinogenesis, angiogenesis, and immunity to name a few. Herein, we outline some of the clinically relevant aspects of this intriguing, and rapidly progressing field.
Signaling
In mammalian cells, there are three subtypes of TGF-β ligands, β1, β2, and β3. They are encoded by separate genes, but signal through the same signaling cascade. TGF-β binds to a transmembrane, heteromeric complex of serine/threonine kinases, which are comprised of "type I" and "type II" receptors. Once the TGF-β ligand binds to the receptor complex, TGF-β type II receptor (TβRII) phosphorylates the GS domain of the type I receptor (TβRI). This in turn activates TβRI, which then autophosphorylates itself and phosphorylates downstream target proteins ( Fig. 1) (Roberts and Sporn, 1990; Derynck et al., 2001) .
Smads, a family of proteins, are important mediators in the TGF-β signaling cascade (Shi and Massague, 2003) . Smad2 and Smad3 are bound to SARA (SMAD anchor for receptor activation) in the cytoplasm (Tsukazaki et al., 1998) which presents Smad2 and Smad3 to the activated TGF-β receptor complex. TβRI then directly phosphorylates the carboxy terminal of Smad2 and Smad3, resulting in decreased affinity to SARA and heterotrimerization of Smad2 and Smad3 with Smad4 (Derynck and Zhang, 2003) . This entire complex then translocates into the nucleus via the nucleoporins within the nuclear pore complex (Xu et al., 2002) , and transcriptionally regulates multiple effector genes. The Smad2/3/4 complex's stay within the nucleus is transient, as it becomes dephosphorylated, and shuttled back out to the cytoplasm, where it becomes rephosphorylated to repeat its trip once again (Inman et al., 2002) . Smad6 and Smad7 bind the type I receptor, thereby competitively inhibiting Smad2 and Smad3 phosphorylation (Itoh et al., 2000) . TGF-β induces the expression of Smad7. Therefore, Smad7 acts in a negative feedback loop to regulate the intensity or duration of the TGF-β signal. However, the aberrant expression and the continued presence of Smad7 may cause TGF-β resistance. Smurf1 and Smurf2 are an E3 ubiquitin ligase, which recognize TGF-β activated receptors, and target them for ubiquintylation and degradation (Kavsak et al., 2000) ; (Ebisawa et al., 2001 ). Jab1/CSN5, which is a component of the COP9 signalosome complex, associates constitutively with Smad7 and that overexpression of Jab1/CSN5 causes the translocation of Smad7 from the nucleus to the cytoplasm, promoting its degradation and thus releasing Smad7-mediated suppression of the TGF-β signaling (Kim et al., 2004) .
TGF-β mediated growth inhibition
TGF-β is a potent mediator of growth inhibition in a variety of cell types, including epithelial cells. Downstream targets of TGF-β regulated transcription include p15 INK4B (Hannon & Beach, 1994 ) and p21 CIP1 (Datto et al., 1995) both of which are important "brakes" in the cell cycle. p21 CIP1 , a cyclin dependent kinase inhibitor, interacts with CDK2/cyclin A and CDK2/cyclin E complexes, preventing progression through the cell cycle (Reynisdottir et al., 1995) . In TGF-β mediated cell cycle arrest of human mammary epithelial cells, p15
INK4B
interacts with both CDK4 and CDK6, with loss of cyclin D1, p21
CIP1
, and p27
Kip1 from these complexes. The displaced p27
Kip1 then interacts with CDK2/cyclin E complexes, causing inhibition of this complex (Sandhu et al., 1997) .
In addition, TGF-β inhibits the expression of c-Myc, CDK4, and CDC25A, all of which are involved in driving cellular growth (Derynck et al., 2001) . c-Myc overexpression causes cells to become resistant to TGF-β induced growth suppression (Alexandrow et al., 1995) . Thus, decreasing the levels of c-Myc would repress its inhibitory effects on TGF-β's growth suppression (Warner et al., 1999) . TGF-β also decreases the levels of CDK4 (Ewen et al., 1993) , and CDC25A (Iavarone and Massague, 1997) , a tyrosine phosphatase involved in the activation of CDK4.
TGF-β signaling is also involved in the induction of apoptosis, the mechanism of which is not completely understood at this time. One component identified in rat prostate cancer cells is ARTS (apoptosis-like protein the TGF-β signaling pathway). This molecule sensitizes cells normally resistant to TGF-β induced apoptosis. It is normally found in the mitochondria, but localizes to the nucleus in apoptosis. Expression of a mutant form of ARTS abrogates the activation of caspase 3 and apoptosis (Larisch et al., 2000) . Other proteins that have been implicated in TGF-β induced apoptosis is TIEG1 (TGF-β inducible early response gene) (Tachibana et al., 1997) and DAPK (death-associated protein kinase) (Jang et al., 2002) . 
TGF-β, a tumor suppressor and a tumor promoter
The TGF-β's are a family of ligands that potently inhibit growth and induce apoptosis in nontransformed human colon epithelium. Numerous studies have now demonstrated that the TGF-β receptor complex and its downstream signaling intermediates constitute a tumor suppressor pathway. Inactivation of either of the two transmembrane serine/ threonine kinases called the TβRI and TβRII is now known to underlie a wide variety of human pathologies including carcinogenesis (de Caestecker et al., 2000; Kim et al., 2000) . Human gastric and colon cancers are in general functionally resistant to TGF-β growth inhibition. In human gastric and colon cancers, this resistance is due to the genetic alteration including the mutation of the TβRII resulting from microsatellite instability (Park et al., 1994; Markowitz et al., 1995; Myeroff et al., 1995) . By contrast, the most common mechanism of loss of expression of the TβRII involves transcriptional repression. The observation that TβRII inactivation coincides with acquisition of invasiveness and frank malignancy raises the question of whether TβRII inactivation may directly promote tumor invasiveness as well as release cells from TGF-β mediated growth inhibition. Moreover, TGF-β resistant gastric and colon cancers often produce significant amounts of TGF-β. Such secreted TGF-β could contribute to tumor pathogenesis via paracrine effects on neighboring stromal cells, via inducing the growth of new blood vessels, and via local immune suppression.
Inhibition of TGF-β encourages proliferation of early tumor cells, but paradoxically, in late tumor cells, activation of TGF-β seems to enhance tumor growth and invasion. For instance, in hereditary non-polyposis colorectal cancer (HNPCC), a repeat stretch of adenines in TβRII gene are prone to mutations due to microsatellite instabilities, which give rise to nonfunctional truncated proteins Lu et al., 1996) . And mutations in the TβRII have been found sporadically in gliomas, and as well as in cancers of the colon, stomach, endometrium, pancreas, liver, and breast (Siegel and Massague, 2003) . Overall, 20-25% of all colon cancers have an inactivating mutation in TβRII (Grady et al., 1999) . Mutations of TβRI have been found in ovarian, breast, pancreatic cancers, as well as in T-cell lymphoma (Siegel and Massague, 2003) . And homozygotes of an attenuated form of TβRI allele have a higher risk of developing colon cancer (Pasche et al., 1999) .
Experimentally, expression of wild type TβRII in gastric, colon, or breast cancer cell lines which lack functional TβRII results in growth inhibition and reduced anchorage independence Sun & Chen, 1997; Chang et al., 1997) . And expression of active TGF-β1 in mouse keratinocytes rendered them more resistant to the formation of benign skin lesions in a skin chemical carcinogenesis model (Cui et al., 1996) . These studies suggest that TGF-β is indeed a "tumor suppressor." However, tumors have increased production of TGF-β (Derynck et al., 1987) , not less, which suggests a pro-growth role of this ligand in tumorigenesis (Fig. 2 ). In the experiment described above with mouse keratinocytes, the rate of progression from benign tumors to invasive spindle carcinomas was increased. And transgenic mice expressing TGF-β1 in the liver spontaneously developed hepatocellular tumors (Factor et al., 1997) . Sequestration of TGF-β ligand with soluble TGF-β receptors inhibited metastasis of mammary tumors to the lung (Muraoka et al., 2002) . These studies point to a growth promoting role for TGF-β in late tumorigenesis. Thus, in early tumor development, escape from TGF-β's growth inhibition allows proliferation. However, in late tumorigenesis, TGF-β's effects on the tumor microenvironment, including fibroblasts, endothelial cells, and immune cells, promote angiogenesis and suppress immune response to lead to tumor invasion and metastasis.
Angiogenesis
Growth of new blood vessels from pre-existing ones is essential in supplying the growing tumor's metabolic needs. TGF-β1 is a potent inducer of angiogenesis. It can induce capillary formation of endothelial cells cultured on collagen matrix (Madri et al., 1988) . Transgenic mice lacking functional TGF-β1 or the TβRII are embryonically lethal, in part, due to defects in vasculogenesis and angiogenesis (Martin et al., 1995) . And mice lacking the TβRI have defective angiogenesis. TGF-β1 overexpression in prostate carcinoma enhanced angiogenesis whereas neutralizing antibodies decreased it in immunocompromised mice (Ueki et al., 1992) . TGF-β can induce angiogenesis by increasing the expression of VEGF (vascular endothelial growth factor) (Pertovaara et al., 1994) . TGF-β can also create favorable environmental condition for the growth and maintenance of new blood vessels. It upregulates MMP-2 and MMP-9, which degrade extracellular matrix, and allow for subsequent invasion and migration of endothelial cells (Derynck et al., 2001) . Thus, TGF-β is pro-angiogenic in two ways, first by directly stimulating cytokines involved in endothelial growth, and second by inducing a micro-environment favorable for endothelial migration, invasion, and survival.
Tumor invasion
Invasion through the basement membrane is a critical step in tumor progression and requires transdifferentiation of epithelial cells to mesenchymal type. This involves loss of cell-cell contact, with acquisition of increased fibroblastic characteristics. This transition is commonly referred to as the epithelial-mesenchymal transition (EMT) and is not only found in tumors, but also in development (Siegel and Massague, 2003) . TGF-β plays a critical role in the transdifferentiation of epithelium to mesenchyme of embryonic cardiac, palatal, and hair follicle development (Derynck et al., 2001) . In keratinocytes, the predominant cytoskeleton switches from intermediate filament to vimentin during transdifferentiation (Oft et al., 1996) while there is a decreased expression of E-cadherin, the calcium dependent cell-cell adhesion molecule. Tumors commonly downregulate E-cadherin, and its overexpression can suppress tumor invasion (Thiery, 2002) . Because TGF-β induces expression of SNAIL and SIP1, zinc-finger transcription factors that repress expression of E-cadherin (Comijn et al., 2001) ; (Peinado et al., 2003) , it has been suggested that TGF-β cause differentiation of epithelial cells to those of mesenchymal phenotype, thereby making these cells more invasive, with greater metastatic potential. This hypothesis is supported by the observation that the expression of dominant negative TβRII reversed colon cancer cells to an epithelial phenotype in vitro (Oft et al., 1998) and in squamous cell carcinomas in vivo (Portella et al., 1998) .
Immune suppression TGF-β: negative regulator of immune system
Since its initial discovery by Roberts et al. (1990) , TGF-β has been shown to be a critical negative regulator of immune system. In TGF-β1 knock-out mice, animals die of diffuse autoimmune response 3-4 weeks after birth (Kulkarni et al., 1993) . Further studies have demonstrated that TGF-β inhibits interleukin-2 (IL-2) production, leading to inhibition of T-cell proliferation. In addition, TGF-β inhibits the ability of naïve CD4 and CD8 T cells to develop into mature effector T cells, TH1 or TH2, or cytotoxic lymphocytes, respectively. In macrophages and monocytes, TGF-β is both stimulatory and inhibitory. TGF-β is a potent chemoattaractant for human blood monocytes and activates phagocytic activity in macrophages. However, TGF-β has also been shown to deactivate macrophages by suppressing nitric oxide and reactive oxygen intermediates.
Aside from a direct inhibitory effect of TGF-β on immune cells, TGF-β can act on non-immune cells and can contribute to the immunosuppressive effect in the host. Interactions between thymic stromal cells and immune cells are the basis for T cell selection and have an impact on final T cell repertoire (Sebzda et al., 1999) . For example, TGF-β expressed from thymic stromal cells regulates the differentiation of CD4+/CD8+ double positive stages (Plum et al., 1995) . Another example is the inhibitory effect of TGF-β on the production of IL-7 by non-lymphoid stromal cells, which are important for the development of B cells (Tang et al., 1997) .
Multiple investigators have suggested that the principal immune-suppressive factor secreted by tumor cells is TGF-β (Chouaib et al., 1997; Wojtowicz-Praga, 1997) . Indeed, it has been reported that the overexpression of TGF-β in the highly immunogenic C3H tumors led to tumor growth and escape from immune-surveillance without affecting the levels of expression of MHC I or tumor-specific antigen (TorreAmione et al., 1990) while TGF-β neutralization resulted in MCF-7 tumor rejection (Arteaga et al., 1993) . In addition, transfection of antisense TGF-β in a rat glioma cell line and the Duning rat prostate tumor MatLyLu led to a complete eradication of tumor xenografts in vivo (Fakhrai et al., 1996; Matthews et al., 2000) . Lastly, it has been shown that the overexpression of soluble TβRII resulted in tumor suppression in a mouse thymoma model (Won et al., 1999) . These observations, taken together, support the hypothesis that malignant cells produce TGF-β to escape immune surveillance and suggest that the elimination of TGF-β from tumor cells enhances host anti-tumor immune response.
TGF-β insensitive immune cells and tumor rejection
An alternative to eliminating the production of TGF-β from tumor cells is to render immune cells insensitive to TGF-β. In this regard, Gorelik and Flavell have demonstrated that T-cells transfected with dominant negative form of TβRII (TβRIIDN) were able to reject tumor (Gorelik and Flavell, 2001) . The same authors also reported that the eradication of tumors did not occur if tumors were established 7 days prior to infusion with the TβRIIDN-expressing T-cells. These results suggest that the immune-mediated rejection of established tumors requires additional cell types, in addition to T-cells.
In this regard, the transplantation of TGF-β-insensitive hematopoietic stem cells has been reported to eliminate cancer cells in mice (Shah et al., 2002b) . Unfortunately, the animals eventually died of diffuse inflammation of peripheral organs that is characteristic of graft-versus-host disease (GVHD) at seven months after initiation of treatment. Analysis of these animals demonstrated a dramatic expansion of macrophages (Shah et al., 2002a) . A similar activation of immune cells was also observed in TGF-β knockout animals which showed an excess inflammation in peripheral organs (Kulkarni et al., 1993) .
Wound healing
Wound healing after injury requires a complex coordination of cells, beginning with the influx of inflammatory cells, transdifferentiation of epithelial to mesenchymal cells, mobilization of fibroblasts, then finally laying down of extracellular matrix. Degranulation of platelets at sites of injury releases a bolus of TGF-β1, thereby increasing the production of ECM by inducing various collagen gene promoters (Flanders, 2004) while decreasing ECM degradation by inhibiting matrix degrading enzymes and increasing expression of MMP inhibitors (Yuan and Varga, 2001) .
Topical application of TGF-β improves healing, even in radiation-impaired wounds (Bernstein et al., 1991) . Wound healing is believed to signal mainly through Smad3, but not Smad2. The Smad2 knockout mice are embryonically lethal, and fail to gastrulate, form mesoderm, and have left-right patterning defects (Nomura & Li, 1998) . The Smad3 KO mice have skeletal abnormalities and defects in T-cell immunity Yang et al., 2001 ). In addition, Smad3 null mice have faster cutaneous wound healing, due to the absence of TGF-β mediated growth inhibition of keratinocytes (Ashcroft et al., 1999) . The Smad3 KO mice also have been reported to be resistant to TGF-β-induced pulmonary fibrosis, and to have decreased cutaneous damage and fibrosis following ionizing irradiation (Flanders et al., 2002) .
Aberrant TGF-β signaling has been implicated in pathologic fibrotic conditions involving skin, liver, kidney, eye, lung, and heart (Flanders, 2004) . For instance, increased levels of TGF-β were found in hepatic fibrosis induced by murine schistosomiasis or CCl4-treatment (Czaja et al., 1989) . It is thought that the release of TGF-β by necrotic hepatocytes trigger the transdifferentiation of hepatic stellate cells into fibroblast like cells (Furukawa et al., 2003) . And in the lung, TGF-β seems to be important in the regulation of ECM. Inhalation of adenovirus expressing TGF-β1 can induce pulmonary fibrosis in WT mice, but not in Smad3 null mice (Bonniaud et al., 2004) . However, the Smad3 KO mice develop enlarged airspace, similar to emphysema, due to decreased amounts of ECM. In the kidney, abnormal TGF-β signaling has been suggested to play a role in diabetic nephropathy by increasing glomerulosclerosis and fibrosis. Because TGF-β is intimately involved in wound healing and fibrosis, mediated mostly by its actions on the transdifferentiation of epithelial cells to mesenchymal ones and regulation of ECM, TGF-β may be used to improve wound healing. On the other hand, the inhibition of Smad3 may prevent fibrotic diseases of various organs.
Conclusion
TGF-β is a multi-functional growth factor that has numerous clinical implications. Because TGF-β's effects depend on the context of the experiments, it has been an arduous process to understand the role of TGF-β in clinical pathology. Nevertheless, significant progress has been made in the last few years by many investigators. Further clarification of the precise role of TGF-β in different biological context will likely lead to new and novel therapeutic strategies for various diseases such as cancer, autoimmunity, and pathologic fibrosis.
